Get the Stockscreener App
162.51
5.28%
8.15
Repligen Corp stock is traded at $162.51, with a volume of 890.21K.
It is up +5.28% in the last 24 hours and up +3.67% over the past month.
Repligen, headquartered in Waltham, Massachusetts, is a global life sciences company that develops and sells bioprocessing equipment and supplies used in the manufacturing of biologic drugs, including monoclonal antibodies, recombinant proteins, vaccines, and cell and gene therapies. Its customers include biopharmaceutical companies, contract development and manufacturing organizations, or CDMOs, and other life science companies. It sells four main product categories: filtration (including fluid management) is the largest category and was 58% of 2024 revenue, while chromatography, proteins, and process analytics were 19%, 12%, and 9%, respectively. Customers in North America, Europe, and Asia Pacific contributed 44%, 37%, and 19% of revenue, respectively.
See More
Previous Close:
$154.36
Open:
$156.5
24h Volume:
890.21K
Relative Volume:
0.96
Market Cap:
$9.15B
Revenue:
$633.51M
Net Income/Loss:
$-8.10M
P/E Ratio:
-524.23
EPS:
-0.31
Net Cash Flow:
$131.26M
1W Performance:
+6.65%
1M Performance:
+3.67%
6M Performance:
+35.19%
1Y Performance:
+14.64%
1-Day Range:
$155.72
$164.39
1-Week Range:
$146.56
$164.39
52-Week Range:
$102.97
$182.52
Repligen Corp Stock (RGEN) Company Profile
Name
Repligen Corp
Sector
Industry
Phone
(781) 449-9560
Address
41 SEYON STREET, WALTHAM, MA
Compare RGEN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
RGEN
Repligen Corp
|
162.51 | 8.69B | 633.51M | -8.10M | 131.26M | -0.31 |
|
ISRG
Intuitive Surgical Inc
|
561.61 | 195.76B | 9.61B | 2.77B | 2.27B | 7.555 |
|
BDX
Becton Dickinson Co
|
192.72 | 54.34B | 21.84B | 1.68B | 2.67B | 5.8322 |
|
ALC
Alcon Inc
|
76.61 | 36.86B | 10.19B | 1.05B | 1.38B | 2.1044 |
|
RMD
Resmed Inc
|
250.75 | 35.60B | 5.26B | 1.44B | 1.76B | 9.7713 |
|
WST
West Pharmaceutical Services Inc
|
271.07 | 18.54B | 2.96B | 487.70M | 344.00M | 6.6758 |
Repligen Corp Stock (RGEN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-01-25 | Initiated | HSBC Securities | Buy |
| Sep-22-25 | Upgrade | Evercore ISI | In-line → Outperform |
| Jul-22-25 | Resumed | Stephens | Overweight |
| Jun-24-25 | Initiated | Barclays | Overweight |
| Apr-29-25 | Upgrade | Wolfe Research | Peer Perform → Outperform |
| Mar-18-25 | Initiated | Evercore ISI | In-line |
| Feb-10-25 | Initiated | TD Cowen | Buy |
| Dec-17-24 | Initiated | Canaccord Genuity | Hold |
| Nov-14-24 | Initiated | Wolfe Research | Peer Perform |
| Aug-28-24 | Initiated | Wells Fargo | Overweight |
| Jun-26-24 | Upgrade | Deutsche Bank | Hold → Buy |
| Jun-18-24 | Initiated | Guggenheim | Neutral |
| Dec-04-23 | Downgrade | The Benchmark Company | Buy → Hold |
| Jul-20-23 | Initiated | Wells Fargo | Overweight |
| Jul-05-23 | Resumed | JP Morgan | Overweight |
| Mar-28-23 | Initiated | The Benchmark Company | Buy |
| Dec-14-22 | Initiated | Deutsche Bank | Hold |
| Dec-07-22 | Initiated | RBC Capital Mkts | Sector Perform |
| Jul-20-22 | Initiated | UBS | Buy |
| Oct-14-21 | Initiated | Exane BNP Paribas | Outperform |
| Nov-10-20 | Initiated | KeyBanc Capital Markets | Overweight |
| Aug-24-20 | Reiterated | H.C. Wainwright | Buy |
| Jun-30-20 | Reiterated | H.C. Wainwright | Buy |
| May-07-20 | Reiterated | H.C. Wainwright | Buy |
| Mar-23-20 | Reiterated | H.C. Wainwright | Buy |
| Nov-15-19 | Initiated | Stifel | Buy |
| Nov-01-19 | Upgrade | First Analysis Sec | Outperform → Strong Buy |
| Oct-15-19 | Initiated | SVB Leerink | Outperform |
| Aug-28-19 | Reiterated | First Analysis Sec | Outperform |
| Aug-23-19 | Resumed | Stephens | Overweight |
| Jul-22-19 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Dec-17-18 | Upgrade | CL King | Neutral → Buy |
| Nov-12-18 | Downgrade | CL King | Buy → Neutral |
| Sep-26-18 | Initiated | H.C. Wainwright | Neutral |
| Dec-08-17 | Initiated | Citigroup | Buy |
| Dec-05-17 | Initiated | JP Morgan | Overweight |
| Nov-13-17 | Initiated | CL King | Buy |
| Oct-02-17 | Upgrade | First Analysis Sec | Equal-Weight → Overweight |
| Jul-21-17 | Initiated | William Blair | Outperform |
| Feb-13-17 | Upgrade | Piper Jaffray | Neutral → Overweight |
View All
Repligen Corp Stock (RGEN) Latest News
P/E Ratio Insights for Repligen - Benzinga
Its Stock Has Paid Off Big Time For Repligen Corp - Setenews
Repligen Corporation (RGEN) Stock forecasts - Yahoo Finance UK
RGEN (Repligen) Book Value per Share : $37.01 (As of Sep. 2025) - GuruFocus
Repligen Corporation (RGEN) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Repligen Chief Operating Officer Sold $331K In Company Stock - Benzinga
Can Repligen Corporation (RGN) stock sustain margin levelsWeekly Volume Report & Target Return Focused Picks - newser.com
How strong is Repligen Corporation stock balance sheetBear Alert & Risk Managed Investment Strategies - newser.com
Using Python tools to backtest Repligen Corporation strategies2025 Sector Review & Short-Term High Return Strategies - newser.com
Insider Sell: James Bylund Sells Shares of Repligen Corp (RGEN) - GuruFocus
REPLIGEN COO James Bylund Sells 2,191 Shares - TradingView
Real time breakdown of Repligen Corporation stock performanceJuly 2025 Opening Moves & Expert Curated Trade Setups - newser.com
Why Repligen Corporation (RGN) stock is upgraded to buyEarnings Overview Summary & Consistent Return Strategy Ideas - newser.com
Is Repligen Corporation (RGN) stock supported by strong fundamentals2025 Short Interest & Verified Short-Term Trading Plans - newser.com
Repligen at Wolfe Research Healthcare Conference: Strategic Growth Insights - Investing.com
Repligen at Jefferies London: Strategic Growth Amid Headwinds - Investing.com
Insider Selling: Repligen (NASDAQ:RGEN) Director Sells $3,092,200.00 in Stock - Defense World
Smart tools for monitoring Repligen Corporation’s price actionWatch List & Safe Entry Point Identification - newser.com
Custom strategy builders for tracking Repligen CorporationDividend Hike & Free Accurate Trade Setup Notifications - newser.com
Will Repligen Corporation (RGN) stock benefit from mergersQuarterly Investment Review & Reliable Volume Spike Alerts - newser.com
How Repligen Corporation stock performs during Fed tightening cyclesWeekly Trade Analysis & Risk Controlled Swing Alerts - newser.com
How Repligen Corporation stock trades before earningsJuly 2025 Weekly Recap & Fast Entry and Exit Trade Plans - newser.com
Is Repligen Corporation a good long term investmentPortfolio Allocation Tips & Market Volatility Strategies - earlytimes.in
How to forecast Repligen Corporation trends using time seriesPortfolio Update Summary & Stepwise Entry and Exit Trade Signals - newser.com
REPLIGEN CORP Director Anthony Hunt Sells 20,000 Shares - TradingView
[Form 4] REPLIGEN CORP Insider Trading Activity - Stock Titan
There is no doubt that Repligen Corp (RGEN) ticks all the boxes. - setenews.com
REPLIGEN Director Anthony Hunt Sells 25,000 Shares - TradingView
Chmn Hunt Files To Sell 20,000 Of Repligen Corp [RGEN] - TradingView
RGEN (Repligen) Total Receivables : $149.0 Mil (As of Sep. 2025) - GuruFocus
Repligen stock rating reiterated at Buy by Stifel on strong business outlook - Investing.com
RGEN (Repligen) Inventories, Finished Goods : $72.2 Mil (As of Sep. 2025) - GuruFocus
Lantheus, Enovis, Evolent Health, Repligen, and Corcept Shares Are Soaring, What You Need To Know - Yahoo Finance
Repligen at Stifel Conference: Strong Growth Amid Challenges - Investing.com
Repligen at UBS Global Healthcare: Strategic Growth and Market Positioning - Investing.com
Relative strength of Repligen Corporation in sector analysisPortfolio Return Report & Real-Time Market Sentiment Alerts - newser.com
Repligen Bets Big On Bioprocessing Innovation—But At A Price - Finimize
RGEN (Repligen) Scaled Net Operating Assets : 0.70 (As of Sep. 2025) - GuruFocus
Repligen (RGEN) to Release Earnings on Tuesday - Defense World
Repligen Corp Stock (RGEN) Financials Data
Revenue
Net Income
Cash Flow
EPS
5.11%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):